announce that Microbix external third-party quality assessment products (QAPs®) will be used to support the clinical use of the Allplex™ and Anyplex™ molecular multiplex assays of Seegene Mexico for detecting infection with high-risk types of the human papilloma virus (HPV).

announce that Microbix external third-party quality assessment products (REDx™FLOQ® QAPs®) will be used to support SEKISUI’s U.S. commercialization of the molecular point-of-care assay for diagnosis of COVID/Flu A/Flu B using the Metrix® platform from Aptitude Medical Systems, Inc. (Aptitude).

Microbix announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 26 to 28, 2025.

and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of a program to support rapid and accurate identification of patients who carry gene-variants associated with faster and slower than normal metabolism of the widely-prescribed antiplatelet (anti-clotting) drug Clopidogrel (brand named Plavix®).

Microbix Biosystems announces its hosting of the Honourable Stephen Crawford, Ontario’s Minister of Public and Business Service Delivery and Procurement, for a site visit to tour the company’s advanced biotechnology development and manufacturing facilities and discuss how next generation diagnostics can improve health outcomes while reducing healthcare costs for Ontarians.

Microbix Biosystems reports results for its third quarter and nine months of fiscal 2025 ended June 30, 2025 (“Q3” and “YTD”). Sales for Q3 were down for both Antigens and QAPs™, while YTD Antigens were up and QAPs were down YTD.

Microbix Biosystems announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its third quarter of fiscal 2025 ended June 30, 2025 (“Q3 2025”) prior to the start of trading on August 14, 2025

Microbix Biosystems Inc. announces the commercial launch of QUANTDx™, a new product line of well-characterized reference materials designed to support the development and validation of diagnostic assays.